Handelsavisen
prelaunch
Companies Healthcare EVAX.O
EV
EVAX.O NASDAQ Biotechnology & Life-Science Tools

Evaxion A/S

$2,79
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
23,3M USD
P/E
EV / Rev
Div yield
Op margin
-8 619,6 %
ROE
45,9 %
Net margin
2 341,2 %
Debt / equity
Beta
52w range
Volume
867
Day range
$3,96–$4,23
Prev close
$4,11
Open
$4,10
Next earnings
Ex-dividend
TR 1Y
About

Evaxion A/S is a biotechnology company focused on healthcare diagnostics, developing and commercializing AI-driven vaccine and drug discovery platforms.

Business. Evaxion A/S (EVAX.O) is a biotechnology and medical research company operating within the healthcare diagnostics sector. The firm is headquartered in Denmark and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
BUY4 analysts
4 buy0 hold0 sell
Avg 12m price target11,25

Analyst recommendations

4 analysts · consensus Buy
Buy4
Hold0
Sell0
12-month price target
11,25
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
4 analysts · indicative
Ownership
not yet wired
Profitability
45,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning EVAX.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to EVAX.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Evaxion A/S (EVAX.O) is a biotechnology and medical research company operating within the healthcare diagnostics sector. The firm is headquartered in Denmark and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupBiotechnology & Life-Science Tools
    AI synthesis
    GENERATED

    Evaxion maintains a capital structure with no debt, as indicated by a debt-to-equity ratio of 0.0, and a total equity of $2.6 million. The company's liquidity position is unclear due to the absence of balance-sheet inputs and no going-concern language in source documents. The market capitalization of $34.4 million suggests a small-cap profile, with a price-to-earnings ratio of 28.78, indicating a premium valuation relative to earnings.

    The company's profitability is mixed, with a net income of $1.2 million but an operating loss of $4.4 million. The return on equity of 45.85% is strong, but this is likely driven by the low equity base rather than operational efficiency. The company's performance is not benchmarked against industry medians due to the lack of industry-specific metrics in the provided data.

    Evaxion's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no geographic breakdown provided. The absence of segment or geographic data limits the ability to assess diversification risks or growth opportunities in different markets.

    The company's growth trajectory is uncertain, with no specific revenue growth rates or outlooks provided in the data. Analysts have assigned a mean price target of $11.25, with a median of $10.00, suggesting a potential upside from the current market price of $4.12. However, the lack of detailed revenue history and forward-looking guidance makes it difficult to assess the sustainability of this growth.

    Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language. The dilution risk is currently low, but the company may face pressure to raise additional capital if it continues to operate at a loss. No specific dilution sources are identified in the data, and the probability of near-term dilution remains low.

    Recent events and filings are not detailed in the provided data, so no specific recent developments can be reported. The company's financial statements and analyst estimates are the primary sources of information, with no additional transcripts or filings referenced.

    Key takeaways
    • Evaxion is a biotechnology company with a focus on healthcare diagnostics and AI-driven drug discovery.
    • The company has a strong return on equity but operates at a significant operating loss.
    • The company's capital structure is entirely equity-based, with no debt.
    • Analysts have assigned a mean price target of $11.25, indicating potential upside from the current market price.
    • The company's liquidity risk cannot be assessed due to missing balance-sheet data.
    • The company's growth trajectory is uncertain, with no detailed revenue history or forward-looking guidance provided.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-05
    Q4 2025 · Quarter highlights

    Revenue $0.00, −100,0% YoY; Operating income +63,1% YoY.

    Revenue$0.00−100,0 % YoY
    Operating income-$1.5M+63,1 % YoY
    Net income-$5.9M−63,0 % YoY
    Free cash flow
    EPS
    Operating cash flow-$6.6M+48,8 % YoY
    Financials
    Income statement
    Revenue$0.00
    Gross profit
    Operating income-$1.5M
    Net income-$5.9M
    Balance sheet
    Total assets$28.4M
    Total liabilities$11.4M
    Total equity$17.0M
    Cash & equivalents
    Long-term debt$7.5M
    Cash flow
    Operating cash flow-$6.6M
    CapEx-$11.0k
    Free cash flow
    SBC
    Highlights
    • Revenue $0.00, −100,0% YoY
    • Operating income +63,1% YoY
    • Net income −63,0% YoY

    Valuation TTM

    Market price
    $2,79
    Market cap
    $34.4M
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    45.9%
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryBiotechnology & Life-Science Tools27,7B node revenueIQV 58,8%CRL 14,5%MEDP 9,1%ALKS 5,3%PIII 5,3%ORGO 2,0%NAGE 0,5%SPRY 0,3%Other 4,2%
    Source: company disclosures · own-taxonomy revenue-covered setEVAX 0,0% · rank #38 of 78

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs EVAX · multiples and returns
    IQ
    IQV
    Iqvia Holdings Inc
    $181,94
    30,9B USD
    P/E
    22,7x
    -6,1 vs self
    Div yield
    vs self
    ROE
    21,9 %
    -24,0 vs self
    CR
    CRL
    Charles River Laboratories
    $230,87
    11,4B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -4,6 %
    -50,4 vs self
    ME
    MEDP
    Medpace Holdings Inc
    $576,00
    16,7B USD
    P/E
    34,4x
    +5,6 vs self
    Div yield
    vs self
    ROE
    75,4 %
    +29,5 vs self
    AL
    ALKS
    Alkermes PLC
    $49,53
    8,2B USD
    P/E
    39,8x
    +11,0 vs self
    Div yield
    vs self
    ROE
    8,4 %
    -37,5 vs self
    PI
    PIII
    P3 Health Partners Inc
    $10,20
    73,8M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    95,3 %
    +49,5 vs self
    OR
    ORGO
    Organogenesis Holdings Inc
    $2,38
    306,2M USD
    P/E
    9,0x
    -19,8 vs self
    Div yield
    vs self
    ROE
    8,5 %
    -37,3 vs self
    NA
    NAGE
    Niagen Bioscience Inc
    $3,53
    281,1M USD
    P/E
    17,4x
    -11,4 vs self
    Div yield
    vs self
    ROE
    22,7 %
    -23,1 vs self
    SP
    SPRY
    Ars Pharmaceuticals Inc
    $5,51
    547,1M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -149,9 %
    -195,8 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -1,17
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    4
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-1,17
    Revenueno estimateno estimate5,3M USD
    Operating incomeno estimateno estimate-13,2M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution4 analysts
    Strong buy0
    Buy4
    Hold0
    Sell0
    Strong sell0
    12-month price target$11,25 · Median $10,00
    Low $9,00High $16,00
    Operating income · consensus-13,2M USD
    EPS surprise
    +14,2 %
    reported vs consensus · beat
    Revenue surprise
    +42,6 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$9,00
    Mean$11,25
    Median$10,00
    High$16,00
    Spot$2,79
    +303.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    Op Margin-8 619,6 %Bottom quartile
    Net Margin2 341,2 %Best in class
    ROE45,9 %Best in class
    D/E0,00Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    Source documents
    • Evaxion A/S Market data — financials · 2026-05-27
    • Evaxion A/S Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    20.9Kshares short-28.9% vs prior
    1.11days to cover
    25.5%short of daily vol
    20fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    EVAX.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-12FILINGFORM 6-K →
    2026-06-11FILINGFORM 6-K →
    2026-05-12FILINGFORM 6-K →
    2026-05-07FILINGFORM 6-K →
    2026-05-04FILINGFORM 6-K →
    2026-04-27FILINGFORM 6-K →
    2026-04-22FILINGFORM 6-K →
    2026-04-17FILINGFORM 6-K →
    2026-04-17FILINGFORM 6-K →
    2026-04-16FILINGFORM 6-K →
    2026-04-07FILINGFORM 6-K →
    2026-03-30FILINGFORM 6-K →
    2026-03-05 09:26 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 0.0M · Net USD -5.9M
    2026-03-05 09:26 UTCEARNINGSAnnual results — FY 2026 Revenue USD 7.5M · Net USD -7.7M
    2025-11-06 07:30 UTCEARNINGSQuarterly results — Q3 2025 Revenue USD 7.5M · Net USD 4.6M
    2025-08-14 07:30 UTCEARNINGSQuarterly results — Q2 2025 Revenue USD 0.0M · Net USD -4.8M
    2025-05-27 07:30 UTCEARNINGSQuarterly results — Q1 2025 Revenue USD 0.0M · Net USD -1.6M
    2025-04-01 07:30 UTCEARNINGSQuarterly results — Q1 2025 Revenue USD 0.1M · Net USD -3.6M
    2025-04-01 07:30 UTCEARNINGSAnnual results — FY 2025 Revenue USD 3.3M · Net USD -10.6M
    2024-10-31 09:21 UTCEARNINGSQuarterly results — Q3 2024 Revenue USD 3.0M · Net USD -1.9M
    2024-08-14 07:00 UTCEARNINGSQuarterly results — Q2 2024 Revenue USD 0.2M · Net USD -6.2M
    2024-05-28 08:21 UTCEARNINGSQuarterly results — Q1 2024 Revenue USD 0.1M · Net USD 1.2M
    2024-03-26 16:05 UTCEARNINGSAnnual results — FY 2024 Revenue USD 0.1M · Net USD -22.1M
    2023-04-27 07:36 UTCEARNINGSAnnual results — FY 2023 Net USD -23.2M
    2022-03-22 06:30 UTCEARNINGSAnnual results — FY 2022 Net USD -24.5M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage